Author(s):
Sagar S. Dalvi, Nisha S. Mhaske, Vishal J. Gaikwad
Email(s):
dalvisagar1995@gmail.com
DOI:
10.52711/2321-5836.2024.00054 
Address:
Sagar S. Dalvi1*., Nisha S. Mhaske2, Vishal J. Gaikwad3
1,3Department of Pharmacology, Dr. Naikwadi College of Pharmacy, Jamgaon, Sinnar, Maharashtra, India.
2Department of Pharmacology, PRES’s, College of Pharmacy (D. Pharm & B. Pharm), Chincholi, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2024
ABSTRACT:
Sodium glucose cotransporter type 2 inhibitors (SGLT2i) are a class of antidiabetic drugs whose mechanism of action is based on the reabsorption of filtered glucose via inhibition of sodium-glucose co-transporter 2 in the proximal convoluted renal tubule. Ertugliflozin is the latest in the Series to be approved by the US Food and Drug Administration for type 2 diabetes mellitus (T2DM), with Recent regulatory approvals in the United States (USA) (December 2017), European Union (March 2018), and elsewhere. The clinical and safety profile of individual SGLT2-inhibitors has been investigated in clinical trials in comparison to placebo and other oral anti-diabetic drug classes, as mono-therapy and add-on therapy among patients with T2DM. In vitro and in vivo studies showed that the metabolic profile of ertual hepatic microsomes and hepatocytes is formed by monohydroxylation, O-demethylation and glucuronidation. In a dose-proportional Manner, plasma concentrations (median Tmax) and area under the curve (AUC) increase following single doses from 0.5 mg (0.1 times the lowest Recommended dose) to 300 mg (20 times the highest Recommended Dose) and following multiple dosages from 1 mg (0.2 times the least Recommended dose), Tmax increases by 29% and prolongs Tmax by 1 hour, But does not alter AUC as compared with the fasted state. This new drug serves as an alternative drug for the treatment of patients with type 2DM.
Cite this article:
Sagar S. Dalvi, Nisha S. Mhaske, Vishal J. Gaikwad. Ertugliflozin: A Novel Drug for Control of Type-2 Diabetes. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):315-0. doi: 10.52711/2321-5836.2024.00054
Cite(Electronic):
Sagar S. Dalvi, Nisha S. Mhaske, Vishal J. Gaikwad. Ertugliflozin: A Novel Drug for Control of Type-2 Diabetes. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(4):315-0. doi: 10.52711/2321-5836.2024.00054 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-4-10
REFERENCES:
1. Markham A. Ertugliflozin: first global approval. Drugs. 2018 Mar 1; 78(4): 513-9.
2. Miao Z, Nucci G, Amin N, Pharmacokinetics, Metabolism, and excretion of the antidiabetic agent Ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013; 41(2): 445-56.
3. Gould, G.W., Holman, G.D., 1993. The Glucose Transporter Family: Structure, Function.
4. Gould, G.W., Holman, G.D. The glucose transporter family: structure, function and tissue- specific expression. Biochem. J. 1993; 295: 329-341.
5. Joost, H.G., Wandel, S., Schulman, A. Structure-function relationship of Glucose transporters catalyzing facilitated diffusion. Exp. Clin. Endocrinol. 1994; 102: 434-438.
6. Kahn, B.B. Facilitative glucose transporters: regulatory mechanisms and Dysregulation in diabetes. J. Clin. Invest. 1992; 89: 1367-1374.
7. Sheperd, P.R., Kahn, B.B. Glucose transporters and insulin action: implications For insulin resistance and diabetes mellitus. N. Engl. J. Med. 199; 341: 248-257.
8. Andrea Scheepers., Hans Georg Joost., Annette Schurmann. The glucose Transporter families SGLT and GLUT: Molecular basis of normal and aberrant function.J. Parente.r Enteral. Nutr. 2004; 28: 364-371.
9. Piero, M.N., Nzaro, G.M., Njagi, J.M. Diabetes mellitus – a devastating metabolic Disorder. AJBPS. 2014; 4(40): 1-7.
10. Klein, R. Hypoglycemic therapy in patients diagnosed to have diabetes at 30 years of age or older. J. Chronic. Dis. 1984; 37: 159-65.
11. Shih-Li Su. Sodium-Glucose Transporter. Formos.J. Endocrin.Metab.2009; 1: 1-5.
12. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/
13. M, Vaz AD, Callegari E, Kalgutkar AS: Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb; 41(2): 445-56. Doi: 10.1124/dmd.112.049551. Epub 2012 Nov 20.
14. Abdul-Ghani MA, DeFronzo RA: Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008 Sep; 14(6): 782-90. Doi: 10.4158/EP.14.6.782.
15. Dendup T, Feng X, Clingan S, Astell-Burt T: Environmental Risk Factors for Developing Type 2 Diabetes Mellitus: A Systematic Review. Int J Environ Res Public Health. 2018 Jan 5; 15(1). Pii: ijerph15010078. Doi: 10.3390/ijerph15010078
16. Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, Mezza T, Giaccari A: Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017 Oct 3; 11: 2905-2919. Doi: 10.2147/DDDT.S114932. eCollection 2017.
17. Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, et al. Spotlight on ertugliflozin and itsPotential in the treatment of type 2 diabetes: evidence to date. Drug Design Develop Therapy. 2017; 11: 2905.
18. Food and Drug Administration. Center for drug Evaluation and research. Availableat: https://www.accessdata.fda.gov/ drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000MedR.pdf.Accessed dated 10 Oct 18
19. Miazo Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and Excretion of the antidiabetic agent ertugliflozin (PF-04971729) in Healthy male subjects. Drug Metab Dispos. 2013; 41(2): 445-456.
20. Davies MJ, D’Alessio DA, Fradkin J, et al. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41: 2669–2701.